SCHEMBL6312640

SCHEMBL6312640

COc1ccc2ncc(NC(=O)OC(C)(C)C)cc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
HPGD P15428 2/20 0.53
F2 P00734 1/20 0.53
GLA P06280 1/20 0.53
CNR2 P34972 1/20 0.50
ALPL P05186 6/20 0.47
KDM4E B2RXH2 3/20 0.45
GAA P10253 1/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HPGDS O60760 1/20 0.44
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44
MALT1 Q9UDY8 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846497 0.85 CNR2 (0.47) CNR2KDM4EHDAC4HDAC1MALT1
SCHEMBL14784253 0.85 SYK (0.47) KDM4EGAAHDAC4HDAC1MALT1
SCHEMBL14784481 0.84 CNR2 (0.41) CNR2ALPLHDAC4HDAC1HDAC3
SCHEMBL4071391 0.84 MALT1 (0.55) ALPLKDM4EHDAC4HDAC1MALT1
SCHEMBL12101564 0.84 HDAC4 (0.45) KDM4EHDAC4HDAC1MALT1HDAC3
SCHEMBL6313654 0.83 ALDH1A1 (0.59) ALDH1A1HPGDF2GLACNR2
SCHEMBL4672586 0.83 NPC1 (0.50) ALDH1A1HPGDKDM4EGAANPC1
SCHEMBL240482 0.82 TRPV1 (0.61) ALDH1A1HPGDCNR2KDM4EHDAC4
SCHEMBL13783466 0.80 NPC1 (0.51) ALDH1A1GAANPC1RAB9AMAPT
SCHEMBL621741 0.80 MAP4K4 (0.43) ALDH1A1HPGDKDM4EHDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939874-B2 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. (US) 2005-09-06 US disclosed
EP-1427421-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS Amgen Inc. (US) 2004-06-16 EP disclosed
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. 2004-04-01 US disclosed
WO-2003018021-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS AMGEN INC. (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use DPYD, TYMP, TPMT ALDH1A1 433/4885HPGD 165/4885F2 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.